<DOC>
	<DOC>NCT00108758</DOC>
	<brief_summary>This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.</brief_summary>
	<brief_title>Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Diagnosis of congenital haemophilia A or B with inhibitors development against FVIII or FIX, respectively Prophylactic administration of any haemostatic drug within 3 last months prior to entering the trial.</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>